1. Home
  2. MKTX vs GRFS Comparison

MKTX vs GRFS Comparison

Compare MKTX & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MKTX
  • GRFS
  • Stock Information
  • Founded
  • MKTX 2000
  • GRFS 1940
  • Country
  • MKTX United States
  • GRFS Spain
  • Employees
  • MKTX N/A
  • GRFS N/A
  • Industry
  • MKTX Investment Bankers/Brokers/Service
  • GRFS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MKTX Finance
  • GRFS Health Care
  • Exchange
  • MKTX Nasdaq
  • GRFS Nasdaq
  • Market Cap
  • MKTX 6.8B
  • GRFS 7.2B
  • IPO Year
  • MKTX 2004
  • GRFS 2006
  • Fundamental
  • Price
  • MKTX $187.50
  • GRFS $10.13
  • Analyst Decision
  • MKTX Buy
  • GRFS Hold
  • Analyst Count
  • MKTX 11
  • GRFS 1
  • Target Price
  • MKTX $228.09
  • GRFS $10.30
  • AVG Volume (30 Days)
  • MKTX 637.7K
  • GRFS 794.7K
  • Earning Date
  • MKTX 11-05-2025
  • GRFS 01-01-0001
  • Dividend Yield
  • MKTX 1.62%
  • GRFS 1.41%
  • EPS Growth
  • MKTX N/A
  • GRFS 132.60
  • EPS
  • MKTX 5.95
  • GRFS 0.53
  • Revenue
  • MKTX $837,157,000.00
  • GRFS $8,744,226,659.00
  • Revenue This Year
  • MKTX $7.10
  • GRFS $6.00
  • Revenue Next Year
  • MKTX $8.41
  • GRFS $6.71
  • P/E Ratio
  • MKTX $31.48
  • GRFS $24.82
  • Revenue Growth
  • MKTX 7.67
  • GRFS 9.32
  • 52 Week Low
  • MKTX $178.20
  • GRFS $6.19
  • 52 Week High
  • MKTX $296.68
  • GRFS $11.14
  • Technical
  • Relative Strength Index (RSI)
  • MKTX 45.07
  • GRFS 52.17
  • Support Level
  • MKTX $178.20
  • GRFS $9.57
  • Resistance Level
  • MKTX $184.99
  • GRFS $9.99
  • Average True Range (ATR)
  • MKTX 3.86
  • GRFS 0.18
  • MACD
  • MKTX 0.57
  • GRFS -0.05
  • Stochastic Oscillator
  • MKTX 63.01
  • GRFS 51.85

About MKTX MarketAxess Holdings Inc.

Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: